Location determines whether macrophages fight cancer or help it survive
Within the complex ecology of a tumor, not all defenders are equal — some immune cells fight the cancer while others, shaped by their surroundings, quietly serve it. Researchers at Dartmouth Cancer Center have found that the fate of macrophages, the immune system's versatile sentinels, is determined not by what they are but by where they stand: those near airways and blood vessels organize resistance, while those buried deep within tumors become unwitting allies of disease. This discovery challenges the long-held instinct to eliminate macrophages broadly, suggesting instead that medicine's next step is learning to tell friend from foe within the body's own ranks.
- Tumors exploit the immune system's own cells, turning some macrophages into protectors of cancer rather than destroyers of it — a biological betrayal hiding in plain sight.
- Previous therapies that wiped out all macrophages indiscriminately removed the very immune cells keeping tumors in check, explaining years of mixed and disappointing clinical results.
- Dartmouth immunologist Claudia Jakubzick's team demonstrated in preclinical models that removing airway- and vessel-adjacent macrophages accelerated tumor growth, proving their protective role is indispensable.
- The field is now pivoting toward precision: rather than broad elimination, future immunotherapies aim to shield beneficial macrophage populations while selectively neutralizing those that shield tumors from attack.
- No human trials or targeted drugs exist yet, but the conceptual shift — from blunt removal to surgical selectivity — marks a meaningful turning point in how cancer immunotherapy is designed.
Cancer tumors are not isolated masses — they are surrounded by the body's own immune cells, and not all of those cells are fighting on the same side. New research from Dartmouth Cancer Center, led by immunologist Claudia Jakubzick and published in Nature Immunology, reveals that macrophages — immune cells responsible for clearing debris and coordinating responses to infection — behave in fundamentally opposite ways depending on where they are positioned within a tumor.
Macrophages near the lung's airways and blood vessels act as organizers of anti-cancer immunity, producing signals that recruit other immune cells and slow disease progression. When these cells were removed in preclinical models, tumors advanced more rapidly. A separate population of macrophages, however, accumulates deep within tumor tissue and creates an environment that actively supports tumor survival — working against the very patient they inhabit.
This spatial distinction reframes a long-standing puzzle. Because these macrophage populations look nearly identical under a microscope and share the same surface markers, they have historically been treated as a single category. That assumption helps explain why broad macrophage elimination in cancer therapy has produced inconsistent results: destroying all macrophages means dismantling the immune system's own frontline defenses alongside the harmful ones.
Jakubzick's findings point toward a more precise therapeutic strategy — one that preserves and strengthens the macrophages organizing anti-tumor immunity while selectively blocking those that shelter cancer from attack. The research has not yet reached human trials, and drugs capable of distinguishing between these populations do not yet exist. But the direction is clear: cancer immunotherapy is moving away from blunt elimination and toward strategies that work with the body's natural defenses rather than inadvertently against them.
Cancer tumors are not islands. They are surrounded by immune cells—the body's own defenders—yet not all of these cells are fighting on the same side. Some rally the immune system to attack the cancer. Others, surprisingly, help the tumor survive and spread. The difference, according to new research from Dartmouth Cancer Center, comes down to a single factor: where these immune cells are positioned within the tumor itself.
The study, led by immunologist Claudia Jakubzick and published in Nature Immunology, focused on macrophages—immune cells whose primary job is to clean up cellular debris and respond to injury or infection. In the context of cancer, however, macrophages have proven difficult to categorize. They look similar under a microscope. They carry the same surface markers that researchers typically use to identify them. Yet they behave in fundamentally different ways depending on their location and origin.
Jakubzick's team discovered that macrophages stationed near the lung's airways and blood vessels act as organizers of anti-cancer immunity. These resident cells produce chemical signals that recruit other immune cells to the tumor site and coordinate a local defense against cancer progression. When researchers removed these macrophages in preclinical models, tumors advanced more rapidly—a clear sign that these cells were essential to slowing disease. Meanwhile, a separate population of macrophages accumulated deep within tumor tissue itself, where they created an environment that actually supported tumor growth and survival.
The finding reframes how scientists should think about macrophages in cancer. They are not simply good or bad. Their role depends entirely on where they sit within the tumor's architecture, what signals they receive from their surroundings, and where they originally came from. This nuance explains why previous attempts to treat cancer by broadly eliminating all macrophages have produced mixed and often disappointing results. Removing every macrophage means destroying the beneficial ones alongside the harmful ones—a blunt approach that can backfire by stripping away the immune system's own anti-cancer defenses.
The implications for future treatment are significant. Rather than pursuing broad macrophage elimination, Jakubzick suggests that the next generation of cancer immunotherapies should be far more selective. The goal would be to preserve and even enhance the macrophages that organize anti-tumor immunity while specifically blocking or neutralizing those that protect the tumor from attack. This precision approach—targeting not all macrophages, but only the ones working against the patient—could avoid the collateral damage of previous strategies.
The work remains early. Researchers have not yet translated these findings into human trials or developed drugs that can distinguish between beneficial and harmful macrophage populations. But the direction is clear: cancer immunotherapy is moving toward a more granular understanding of the immune cells surrounding tumors, away from one-size-fits-all elimination and toward strategies that work with the body's natural defenses rather than against them.
Citações Notáveis
Macrophages are not simply 'good' or 'bad.' Different populations play very different roles depending on where they are, where they came from, and the signals they produce.— Claudia Jakubzick, Dartmouth Cancer Center
Past efforts to broadly target all macrophages in cancer have had mixed results because removing them eliminates the ones helping the immune system respond.— Claudia Jakubzick
A Conversa do Hearth Outra perspectiva sobre a história
So the macrophages in the same tumor are doing opposite things depending on where they sit?
Exactly. It's like having security guards in the same building, but some are protecting the building from intruders while others are helping the intruders hide.
Why does location matter so much? What's different about the deep tumor environment?
The signals are different. Near blood vessels and airways, macrophages get cues that tell them to recruit other immune cells. Deep inside the tumor, they're bathed in different chemical signals that tell them to create a protective environment instead.
If we've known macrophages exist in tumors for years, why didn't we figure this out sooner?
Because they looked identical under a microscope. We needed better tools to track where they came from and what they were actually doing, not just what they looked like.
So past cancer drugs that killed all macrophages were actually harming the immune response?
Yes. You were removing your own defenders along with the tumor's protectors. It's why those treatments had such mixed results.
What would a selective therapy actually do?
It would leave the macrophages near blood vessels alone—let them keep organizing the anti-cancer response—while specifically blocking the ones deep in the tumor that are creating a safe space for cancer to grow.